Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 4,342 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Time Management Clear all

Conditions: Esophageal Dysmotility
Interventions: Bethanechol; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Tuberculosis
Interventions: PNU-100480, Placebo; Drug
Lead sponsor: Sequella, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Adenocarcinoma of Prostate
Interventions: Dashboard; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Failed Labour
Interventions: Prepidil Gel, Urinary Balloon Catheter, Combined Urinary Catheter & Prepidil Gel; Drug · Device · Other
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Type 2 Diabetes Mellitus
Interventions: Efpeglenatide SAR439977, Placebo, Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 22
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more

Conditions: Microbiome, Cytokines, Plaque, Gingivitis, Gingival Bleeding
Interventions: Distilled Water, Marketed Comparator 1, Marketed Comparator 2, Prototype Rinse 1, Prototype Rinse 2; Other
Lead sponsor: Kenvue Brands LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Primary Pulmonary Hypertension
Interventions: LIQ861 Inhaled Treprostinil; Drug
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more

Conditions: Rheumatoid Arthritis, Systemic Lupus Erythematosus
Interventions: Surovatamig; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Birmingham, Alabama • Fullerton, California • Plantation, Florida + 3 more

Conditions: Post Menopausal
Interventions: videodance, Brisk Walking, delayed entry control; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years to 65 Years · Female only
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pain, Postoperative
Interventions: Single shot interscalene nerve block, Continuous interscalene nerve block, Local Infiltration Analgesia (LIA); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: CHF - Congestive Heart Failure
Interventions: Digital Outreach; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 13,714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pleasanton, California

Conditions: Patent Foramen Ovale, Intrapulmonary Arteriovenous Anastamosis
Interventions: Sildenafil, Placebo; Drug · Other
Lead sponsor: University of Oregon; Other
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Mental Health Conditions, Developmental Disability
Interventions: Intake and quarterly assessment:, Consultation & coping skills coaching:, 24-hour urgent crisis response and intervention:, Service linkages, referrals, outreach, & training:; Other
Lead sponsor: University of New Hampshire; Other
Eligibility: 12 Years to 45 Years
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Concord, North Carolina

Conditions: Substance Use Disorders
Interventions: Motivational Interviewing, Telephone counseling, Cognitive Behavioral Therapy (CBT) Counseling, medication management, Intensive OutPatient Therapy; Behavioral · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease, Vascular Disease, Arterial Occlusive Disease, Arteriosclerosis, Atherosclerosis, Cardiovascular Disease, Pathologic Processes, Orthopedic Procedures, Amputation
Interventions: Allogeneic bone marrow derived mesenchymal stem cells; Biological
Lead sponsor: Indiana University; Other
Eligibility: 40 Years to 90 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cancer
Interventions: FDA explanation for progression-free survival (control), FDA explanation for progression-free survival with overall survival data, NCI explanation for progression-free survival, NCI explanation for progression-free survival with overall survival data, Plain-language explanation of progression-free survival, Plain-language explanation of progression-free survival with overall survival data; Other
Lead sponsor: London School of Economics and Political Science; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: Positive Outcomes for Women; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Prostate Adenocarcinoma
Interventions: C-11 choline PET tracer, Gadobutrol, PET/MR scanner; Drug · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Hypotension, Postural
Interventions: Pyridostigmine Bromide, Tilt table test; Drug · Device
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Hypercholesterolemia, ASCVD
Interventions: Referral to Pharmacist-Driven Medication Management Program, Best-Practice Alert; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 95 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Enhancing Brain Lesions
Interventions: SubtleGAD, Gadobutrol; Device · Drug
Lead sponsor: Subtle Medical; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Peoria, Illinois • Worcester, Massachusetts • Rochester, Minnesota + 2 more

Conditions: Breast Cancer
Interventions: questionnaire administration, digital mammography, positron emission mammography; Other · Procedure
Lead sponsor: Boston Medical Center; Other
Eligibility: 35 Years and older · Female only
Enrollment: 193 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Age-related Macular Degeneration
Interventions: Diagnostics; Diagnostic Test
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 60 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Hepatitis B
Interventions: standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI); Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 71 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 17
States / cities: Beverly Hills, California • Coronado, California • Los Angeles, California + 10 more

Search by objective public record fields.

Topical Bethanechol for Improvement of Esophageal Dysmotility

Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults

Devel. and Eval. of an Active Surveillance Decision Aid for Men With Low or Intermediate Grade Prostate Cancer

Comparison of Pre-Induction Cervical Ripening

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

Comparison of the Effects of Oral Hygiene Regimens on Clinical, Immunomodulatory, and Microbial Outcomes and Oral Tolerance in People With Gingivitis

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

Adherence and Health Effects of Video Dance in Postmenopausal Women

Analgesic Efficacy of Interscalene Nerve Block Versus Local Infiltration Analgesia Following Total Shoulder Arthroplasty

Digital Outreach for Heart Failure Adherence

Is Blood Flow Through IPAVA and PFO Related to Breath-hold and SCUBA Diving-induced Pulmonary Hypertension?

Evaluation of Telehealth Services on Mental Health Outcomes for People With Intellectual and Developmental Disabilities

Adaptive Treatment for Alcohol and Cocaine Dependence

A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation

Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival

Diabetes Prevention Programming for Women With a History of Gestational Diabetes

Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI

Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI

Improving Lipid Optimization Quality and Treatment Options in ASCVD

MR Image Synthesis With Low Gadobutrol Dose and AI

Positron Emission Mammography and Standard Mammography in Women at High Risk of Breast Cancer

Global Atrophie Biomarker Evaluation Study (GABiE)

A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients